Patient demographics on enzyme replacement therapy
| Post-treatment | Baseline | Year 1 | Year 2 | Year 5 | Year 7 | Year 10 |
|---|---|---|---|---|---|---|
| Age (year) | ||||||
| Non-CKD5 | 34.3±11.2* | 35.3±11.2 | 36.3±11.2 | 36.1±9.2 | 38.1±9.2 | 41.1±9.2 |
| CKD5 | 43.6±8.8* | 44.6±8.8 | 44.7±9.2 | 44.6±8.0 | 45.3±8.0 | 45.6±5.0 |
| Hypertension (%) | ||||||
| Non-CKD5 | 20 (3/15) | 20 (3/15) | 20 (3/15) | 16.7 (2/12) | 16.7 (2/12) | 25 (3/12) |
| CKD5 | 33.3 (3/10) | 44.4 (4/9) | 55.5 (5/10) | 66.6 (4/6) | 66.6 (4/6) | 60 (3/5) |
| Heart rate (bpm) | ||||||
| Non-CKD5 | 55.4±7.5 | 54.9±8.3 | 53.6±5.9 | 53.8±7.3 | 54.6±11.6 | 52.9±7.0 |
| CKD5 | 64.6±16.8 | 59.5±12 | 61.3±10.4 | 61.4±10.4 | 56±7.7 | 56.6±7.0 |
| GFR (mL/min/1.73 m2) | ||||||
| Non-CKD5 | 86.9±16.6 | 83.9±19.1 | 88.5±21.7 | 86.5±21.7 | 84.0±26.4 | 82.4±25.4 |
Non-CKD5 cohort size: baseline (N=15), year 1 (N=15), year 2 (N=15), year 5 (N=12), year 7 (N=12) and year 10 (N=12).
CKD5 cohort size: baseline (N=10), year 1 (N=9), year 2 (N=10), year 5 (N=6), year 7 (N=6) and year 10 (N=5).
*Baseline age non-CKD5 versus CKD5 not statistically different (p=0.09).
CKD5, chronic kidney disease stage 5; GFR, glomerular filtration rate as determined by renal clearance of radionuclide 51Cr-EDTA corrected to body surface area.